New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
14:09 EDTJNJ, IDIX, BMY, MRK, ABBV, ACHNIdenix high premium bodes well for Achillion, says Leerink
Leerink believes the high premium that Merck (MRK) paid for Idenix (IDIX) is a positive sign for Achillion (ACHN), which is the last biotech with a fully-owned nucleotide. The firm noted that media reports said Johnson & Johnson (JNJ), AbbVie (ABBV), and Bristol-Myers (BMY) also expressed interest in Idenix during its sale process. Leerink also said it thinks Merck's commitment to HCV may have a bigger impact on Gilead's (GILD) valuation than its potential market share loss.
News For IDIX;ACHN;MRK;JNJ;ABBV;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 13, 2015
08:08 EDTMRKEli Lilly, Merck enter collaborationa greement to evaluate Keytruda, compounds
Merck (MRK) and Eli Lilly and Company (LLY) announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer. This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
08:05 EDTBMYBristol-Myers Eli Lilly enter clinical collaboration pact for Opdivo combo
Subscribe for More Information
07:45 EDTJNJFierce Biotech to hold a breakfast meeting
Subscribe for More Information
07:42 EDTBMYJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
06:10 EDTACHNAchillion implied volatility of 98 at lower end of index mean range
Subscribe for More Information
January 12, 2015
09:00 EDTBMYBristol-Myers price target raised to $70 from $62 at Argus
Subscribe for More Information
08:37 EDTJNJ, MRK, BMYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:15 EDTBMYSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:06 EDTBMYBristol-Myers shares expected to trade up around 10% at JPMorgan
JPMorgan expects shares of Bristol-Myers to trade up around 10% after the company announced that its Phase III trial of Opdivo in 2L squamous non-small cell lung cancer is stopping early due to efficacy. The firm views the news as a "clear positive" that sets up a potential 2015 filing and launch for the product in the 2L squamous market. It reiterates an Overweight rating on shares of the Bristol-Myers. The stock is up 7% to $64.25 in pre-market trading.
08:01 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
The FDA has approved AbbVie's DUOPA enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. DUOPA was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S.
07:21 EDTJNJ, MRKEBD Group to hold a conference
Subscribe for More Information
07:17 EDTABBVJPMorgan to hold a conference
Subscribe for More Information
07:07 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:05 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
07:04 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:03 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
06:53 EDTMRKMerck to speed up plans for drug submission, WSJ says
Merck is speeding up its plans to submit new drugs for lung cancer and hepatitis C for regulatory approval, reports the Wall Street Journal. The company will file an application with the FDA around the mid-2015 to expand the use of Keytruda, the Journal adds. Reference Link
06:22 EDTMRKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use